AMGEN Inc
NASDAQ: AMGN
$321.91
+$0.12 (+0.0%)
Closing Price on November 7, 2024
AMGN Articles
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
Published:
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Published:
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
While the volume for insider trading has dropped dramatically due to earnings reporting, some very large trades hit the tape this week.
Published:
A new research report from Cowen features three top stocks of companies that exceeded earnings estimates that the firm feels should be bought now.
Published:
Thursday's top analyst upgrades, downgrades and initiations include Barrick Gold, Facebook, Halcon Resources, Qualcomm, Synchrony Financial and Texas Instruments.
Published:
Amgen reported better-than-expected first-quarter 2015 earnings Tuesday afternoon after equity markets had closed.
Published:
Last Updated:
After markets close on Tuesday, Amgen, the second-largest biotech, is scheduled to announce its first-quarter results.
Published:
Last Updated:
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected biotech stocks, short interest has increased.
Published:
Jon OggIf there is one firm on Wall Street that investors have been told that they want to pay attention to during analyst upgrades and downgrades, it is Goldman Sachs. The firm has analysts who are...
Published:
DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend. Should investors should expect a big stock buyback?
Published:
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
Published: